Friday, December 9, 2022, 3:15 PM – 5:15 PM CT (4:15 PM – 6:15 PM ET) – New Orleans, Louisiana

Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma — What Clinicians Want to Know (Part 2 of a 3-Part Series)

A CME Friday Satellite Symposium and Virtual Event Preceding the 64th ASH Annual Meeting

Location
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Hotel Phone: (504) 561-1234

Program Schedule — Central Time
3:00 PM – 3:15 PM — Registration and Snacks
3:15 PM – 5:15 PM — Educational Meeting

Meeting Room
Celestin Ballroom ABCD (Level 3)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in New Orleans, preregistration is required as seating is limited.  
 
Faculty
Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

David G Maloney, MD, PhD
Professor, Clinical Research Division
Medical Director
Cellular Immunotherapy and the Bezos Family Immunotherapy Clinic
Leonard and Norma Klorfine Endowed Chair
for Clinical Research
Fred Hutchinson Cancer Center
Professor of Medicine, Division of Oncology
University of Washington
Seattle, Washington


Loretta J Nastoupil, MD
Associate Professor
Section Chief, Indolent Lymphoma
Section Chief, New Drug Development
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Sonali M Smith, MD
Elwood V Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Co-Leader, Cancer Service Line
Co-Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Kite, A Gilead Company, MEI Pharma Inc, Novartis, and Seagen Inc.
Program Schedule — Central Time
3:00 PM – 3:15 PM — Registration and Refreshments
3:15 PM – 5:15 PM — Educational Meeting

MODULE 1: Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Friedberg

  • Key findings from the Phase III POLARIX study comparing polatuzumab vedotin in combination with chemoimmunotherapy to R-CHOP for untreated DLBCL
  • Available data with and ongoing and planned evaluation of other novel agents for DLBCL in the first-line setting (eg, tafasitamab, loncastuximab tesirine)
  • Published research findings with polatuzumab vedotin and bendamustine/rituximab (BR) for relapsed/refractory (R/R) DLBCL
  • Major efficacy and safety data with tafasitamab/lenalidomide for R/R DLBCL
  • Loncastuximab tesirine: Mechanism of action, available data and optimal sequencing
  • Available data with and ongoing and planned evaluation of novel bispecific antibodies for DLBCL

MODULE 2: Follicular Lymphoma (FL) — Dr Nastoupil

  • Integration of obinutuzumab into current FL treatment; final analysis of the Phase III GALLIUM study
  • Long-term clinical trial findings with lenalidomide/rituximab for treatment-naïve and R/R FL
  • Key findings from the Phase III CHRONOS-3 trial evaluating copanlisib with rituximab for R/R FL
  • Mechanism of action of, available findings with and ongoing Phase III evaluation of zandelisib in R/R FL
  • Mechanism of action of and available data with investigational bispecific antibodies for R/R FL; FDA priority review status for mosunetuzumab
  • Early results with and ongoing investigation of other novel agents and strategies for FL

MODULE 3: Hodgkin Lymphoma (HL) — Dr Smith

  • Long-term follow-up from the Phase III ECHELON-1 trial; selection of patients with advanced classical HL for first-line brentuximab vedotin (BV) with AVD (doxorubicin/vinblastine/dacarbazine)
  • Early findings with BV-based therapy for early-stage, unfavorable-risk HL
  • Available data with and current role of BV for older patients with newly diagnosed advanced HL
  • Potential role of BV alone or with immune checkpoint inhibition as a bridge to transplant for patients experiencing disease progression on up-front treatment
  • Mechanism of action of and available efficacy and safety findings with camidanlumab tesirine for patients with R/R HL; potential role in practice
  • Other promising investigational strategies for patients with HL

MODULE 4: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Non-Hodgkin Lymphoma — Dr Maloney

  • Long-term findings with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tis-cel) and lisocabtagene maraleucel (liso-cel) for patients with multiregimen-relapsed DLBCL
  • Available results from Phase III studies evaluating CAR T-cell therapy as second-line treatment for DLBCL; recent FDA approval of axi-cel and liso-cel in this setting
  • Early findings with other CAR T-cell platforms in DLBCL
  • Key findings with brexucabtagene autoleucel and optimal integration into current mantle cell lymphoma management; ongoing assessment of other CAR T-cell platforms
  • Principal outcomes from pivotal studies evaluating CAR T-cell therapy for FL (eg, ZUMA-5, ELARA); FDA approval of axi-cel and tis-cel and current roles in clinical practice

MODULE 5: Mantle Cell Lymphoma (MCL) — Dr Kahl

  • Data supporting the FDA approvals of ibrutinib, acalabrutinib and zanubrutinib for R/R MCL; key factors in selecting a Bruton tyrosine kinase (BTK) inhibitor
  • Available (SHINE) and emerging (TRIANGLE) Phase III data sets evaluating ibrutinib-based therapy for newly diagnosed MCL
  • Early data with other BTK inhibitor-based combination regimens in previously untreated MCL
  • Mechanisms of resistance to BTK inhibition; key findings from the Phase I/II BRUIN study of pirtobrutinib for R/R MCL
  • Available data with, current role of and ongoing trials assessing venetoclax alone or with other agents for MCL
  • Ongoing investigation of other novel agents and strategies for MCL

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand published research data informing the selection, sequencing and combining of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those therapies in clinical practice.
  • Consider patient age, performance status and other clinical and biologic factors in the selection of up-front and subsequent therapy for mantle cell lymphoma (MCL).
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Assess available clinical trial findings informing the utilization of CD19-directed chimeric antigen receptor T-cell therapy for R/R DLBCL, MCL and FL, and counsel appropriately selected patients regarding the potential benefits of this strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for FL, DLBCL, MCL and HL to support quality of life and continuation of treatment.
  • Recall new data with agents and strategies currently under investigation for HL and various forms of non-Hodgkin lymphoma, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Friedberg and Dr Kahl have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Maloney — Advisory Committee: Chimeric Therapeutics, Genentech, a member of the Roche Group; Consulting Agreements: Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Gilead Sciences Inc, Incyte Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, Lilly, Mustang Bio, Novartis, Umoja Biopharma; Contracted Research: Celgene Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech. Dr Nastoupil — Advisory Committee: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Novartis, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol-Myers Squibb Company, Caribou Biosciences Inc, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, IGM Biosciences Inc, Janssen Biotech Inc, Kite, A Gilead Company, Novartis, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma, Genentech, a member of the Roche Group, MEI Pharma Inc, Takeda Pharmaceuticals USA Inc. Dr Smith — Consulting Agreements: Bristol-Myers Squibb Company, Gilead Sciences Inc, MorphoSys; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Bristol-Myers Squibb Company, Celgene Corporation, Curis Inc, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc; Nonrelevant Financial Relationship: Spouse is employed at Caris Life Sciences.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Kite, A Gilead Company, MEI Pharma Inc, Novartis, and Seagen Inc.

Location
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113
Phone: (504) 561-1234

Meeting Room
Celestin Ballroom ABCD (Level 3)

Directions
Hyatt Regency New Orleans is conveniently located 6 minutes (1.1 miles) from the Ernest N Morial Convention Center, where the 64th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels.

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.

​ ​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this in-person event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our onsite registration desk will be open at 2:45 PM CT on Friday, December 9th. If you are interested in attending, please visit our registration desk outside the Celestin Ballroom ABCD (Level 3) of the Hyatt Regency New Orleans hotel (601 Loyola Avenue).

Hyatt Regency New Orleans is conveniently located 6 minutes (1.1 miles) from the Ernest N Morial Convention Center, where the 64th ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

NOTICE:
Registration for this event is independent of registration for the ASH Annual Meeting.

LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.